» Articles » PMID: 36217150

High Platelet-to-lymphocyte Ratios in Triple-negative Breast Cancer Associates with Immunosuppressive Status of TILs

Abstract

Background: Rating lymphocytes (TILs) are a prognostic marker in breast cancer and high TIL infiltration correlates with better patient outcomes. Meanwhile, parameters involving immune cells in peripheral blood have also been established as prognostic markers. High platelet-to-lymphocyte ratios (PLRs) and neutrophil-to-lymphocyte ratios (NLRs) are related to poor outcomes in breast cancer, but their mechanisms remain unknown. To date, TILs and these parameters have been examined separately.

Methods: We investigated the relationship between TILs and the peripheral blood markers, PLR and NLR, in the same patients, using surgical specimens from 502 patients with invasive breast carcinoma without preoperative chemotherapy. For analysis of triple-negative breast cancer (TNBC) patient outcomes, 59 patients who received preoperative chemotherapy were also examined. For immune cell profiling, multiplexed fluorescent immunohistochemistry (mfIHC) of CD3, CD4, CD8, FOXP3 and T-bet, was conducted.

Results: A positive correlation between PLR and TIL was observed in TNBC (P = 0.013). On mfIHC, tumors in patients with high PLR and NLR contained more CD3CD4FOXP3 T-cells (P = 0.049 and 0.019, respectively), while no trend was observed in CD8 T-cells. TNBC patients had different patterns of outcomes according to TIL and PLR, with the TIL-high/PLR-low group having the lowest rate of disease relapse and death, and the longest distant metastasis-free and overall survivals, while the TIL-low/PLR-high group had the shortest survivals.

Conclusions: Our data suggest that the combination of PLR with TIL assessment may enable more accurate prediction of patient outcomes with TNBC.

Citing Articles

Dynamic monocyte changes as prognostic indicators in operable gastric cancer: a retrospective cohort analysis.

Jiang Y, Sun X, Yang C, Song D, Zhou C, Chen X Front Oncol. 2025; 15:1514281.

PMID: 39990694 PMC: 11842267. DOI: 10.3389/fonc.2025.1514281.


Platelet stimulation-regulated expression of ILK and ITGB3 contributes to intrahepatic cholangiocarcinoma progression through FAK/PI3K/AKT pathway activation.

Yao W, Zhao K, Li X Cell Mol Life Sci. 2024; 82(1):19.

PMID: 39725790 PMC: 11671465. DOI: 10.1007/s00018-024-05526-3.


Real‑world evaluation of the efficacy of immune checkpoint inhibitors in the treatment of metastatic breast cancer.

Qian X, Tao Y, Chen H, Li X, Wang Y, Xu X Oncol Lett. 2024; 29(1):29.

PMID: 39512498 PMC: 11542155. DOI: 10.3892/ol.2024.14775.


Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.

Wang D, Zhang J, Bu C, Liu G, Guo G, Zhang Z J Cancer Res Clin Oncol. 2024; 150(10):466.

PMID: 39422764 PMC: 11489198. DOI: 10.1007/s00432-024-05997-8.


Emerging measurements for tumor-infiltrating lymphocytes in breast cancer.

Wu R, Horimoto Y, Oshi M, Benesch M, Khoury T, Takabe K Jpn J Clin Oncol. 2024; 54(6):620-629.

PMID: 38521965 PMC: 11144297. DOI: 10.1093/jjco/hyae033.


References
1.
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

2.
Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View

3.
Michaeli J, Shaul M, Mishalian I, Hovav A, Levy L, Zolotriov L . Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNFα and NO-dependent mechanism, promoting a tumor-supportive environment. Oncoimmunology. 2017; 6(11):e1356965. PMC: 5674962. DOI: 10.1080/2162402X.2017.1356965. View

4.
Placke T, Kopp H, Salih H . Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun. 2011; 3(4):374-82. DOI: 10.1159/000323936. View

5.
Krenn-Pilko S, Langsenlehner U, Thurner E, Stojakovic T, Pichler M, Gerger A . The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014; 110(10):2524-30. PMC: 4021515. DOI: 10.1038/bjc.2014.163. View